| INTRODUCTION
Endometrial cancer is the most common malignancy of the female genital tract in developed countries, and its incidence is increasing. 1 The overall prognosis of women with endometrial cancer is favourable, but approximately 20% of patients will die of the disease.
Analysis of factors to identify patients with more aggressive disease is one approach for individualised treatment. The appropriate decision for more extensive follow-up and aggressive treatment may reduce the mortality of endometrial cancer.
Endometrial cancers can spread into the abdominal cavity through the intact fallopian tube, resulting in extrauterine extension with positive peritoneal cytology (PPC) despite the absence of invasion of the serosa in the uterine body. In the International Federation of Gynecology and Obstetrics (FIGO) 1988 staging system, PPC was defined as one factor with which to determine stage IIIA. However, this definition was not included in FIGO 2008, which was revised for the first time in 20 years, because the independency of PPC per se as a prognostic factor had yet to be clarified. 2 Incidentally, PPC was considered a recommendation instead of a requirement in FIGO 2008. However, some reports indicate that PPC is a predictive factor for endometrial cancer. [3] [4] [5] [6] Indeed, some cancers with PPC result in early relapse and death. These confounding issues have been in continuous debate even after updating the FIGO staging system.
Caspase-3 is a cysteine protease that plays a central role in execution of apoptosis. [7] [8] [9] It is synthesised as an inactive proenzyme, procaspase-3, which is activated by cleavage during apoptosis. The activated form is called cleaved caspase-3 (CC3) and plays pivotal roles in apoptosis induced through at least two pathways: the intrinsic (mitochondrial) pathway and extrinsic (death receptor-mediated) pathway. CC3 is responsible for specific cleavage of many key cellular proteins associated with apoptosis. [7] [8] [9] Polymorphisms and haplotypes of the caspase-3 gene are risk factors for endometrial cancer. 10 However, although few immunohistochemical studies have assessed the association between the expression levels of CC3 and survival of patients with cancer using an antibody specific for CC3
(unreactive to procaspase-3), [11] [12] [13] [14] [15] whether CC3 expression is involved in the prognosis of endometrial cancer remains unclear.
Ki-67 is commonly used as an excellent marker to define the proliferation status of tumour cells because its expression is found during all active phases of the cell cycle (G1, S, G2, and M) but is lost in the resting phase (G0). 16 However, the prognostic value of Ki-67 expression in endometrial cancer also remains controversial. [17] [18] [19] [20] [21] Therefore, this study was conducted to assess the association between the prognosis of patients with endometrial cancer with PPC and the expression levels of CC3 and Ki-67 in peritoneal cytology samples as well as to clarify the prognostic significance of CC3
and Ki-67 expression. 
| MATERIALS AND METHODS

| Patients and tumours
| Statistical analysis
The Spearman rank correlation test was applied to assess the strength of correlations between the expression levels of CC3 and Ki-67. Fisher's exact test was used to analyse the association between CC3 and Ki-67 expression and patient age, tumour size, histological type, depth of myometrial invasion or vascular invasion.
The disease-free survival (DFS) and overall survival (OS) rates were estimated using the Kaplan-Meier method, and differences between survival rates were compared by the log-rank test. DFS was defined as the time from the date of surgery to the date of first recurrence.
The exact date of recurrence was defined as the date on which apparent tumours were detected by ultrasonographic or radiological examinations. OS was calculated from the date of surgery to the date of death. Data from the survivors were censored at the last follow-up. Multivariate analyses applying the Cox proportional hazards regression model were used to assess independency as a prognostic factor. Differences with a P value of <.05 were considered statistically significant. All statistical analyses were performed using SPSS ver. 20 (IBM Corp., Armonk, NY, USA). The CC3 and Ki-67 expression levels were not correlated with any clinicopathological parameter including age, tumour size, histological type, depth of myometrial invasion, or vascular invasion (Table 2 ).
| Ethical considerations
| Association of CC3 and Ki-67 expression levels with patient survival in the cohort
The follow-up period for survivors ranged from 7 to 120 months with a median of 44.5 months. At the last follow-up, 87% of patients were still alive, 17% experienced tumour recurrence, and 13% had died of their disease. Table 3 
| DISCUSSION
The clinicopathological significance of PPC remains controversial because of its ambiguity as an independent prognostic factor. [3] [4] [5] [6] 22, 23 Nevertheless, endometrial cancers with PPC occasionally have an unfavourable clinical course. Therefore, it is important to identify the prognostic factors influencing the survival of patients with endometrial cancer with PPC.
The clinicopathological parameters that affect the prognosis of endometrial cancers are widely known to include patient age, tumour size, histological type, depth of myometrial invasion, vascular invasion, extrauterine extension, lymph node metastasis and distant metastasis. 1 In the present study, non-endometrioid histology was an independent factor for shorter DFS and OS with strong statistical significance, whereas no significant associations were found between the other variables and patient prognosis. 15 To the best of our knowledge, no reports have yet The contribution of CC3 Low to a poor prognosis was higher for patients with non-endometrioid tumours. In particular, we identified a subset of patients with a remarkably poor prognosis when they 17, 20, 21 In conclusion, our results suggest that CC3 Low in peritoneal cytology samples is a poor prognostic factor in patients with endometrial cancers, especially non-endometrioid tumours. Immunocytochemical analysis of CC3 expression could potentially facilitate identification of a subgroup of high-risk patients who should be considered equivalent to patients with advanced cancer. However, our results are still exploratory because the number of patients in this study is too small to reach any definitive conclusions. Further studies with a larger cohort are needed to validate our results.
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